Founded in 2005, Viroblock S.A. is a privately held Swiss healthcare company.

Between 2005 and 2011, Viroblock developed a proprietary novel antiviral technology that is both broad spectrum and rapidly acting. This unique technology deactivates the entire class of enveloped viruses, which represents 90% of all human viral pathogens (eg. H1N1, H5N1, RSV, SARS, Herpes, HIV, etc.). Applying Viroblock technology to air filtration products then traps and kills pathogenic viruses and bacteria as they seek to pass through the filter.

The Company is now bringing this technology to the market in a range of air filtration products that help protect users from the increasingly virulent viruses found in today’s world.

Viroblock’s first product is a revolutionary new respiratory mask that traps and kills more than 99.9995% of H1N1 on pass through air.